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The high burden of tuberculosis (TB) among patients accessing antiretroviral treatment (ART) services in
resource-limited settings is a major cause of morbidity and mortality and is associated with nosocomial
transmission risk. These risks are greatly compounded by multidrug-resistant disease. Screening and diagnosis of
TB in this clinical setting is difficult. However, progress has beenmade in defining a high-sensitivity, standardized
symptom screening tool that assesses a combination of symptoms, rather than relying on report of cough alone.
Moreover, newly emerging diagnostic tools show great promise in providing more rapid diagnosis of TB, which is
predominantly sputum smear–negative. These include culture-based systems, simplified versions of nucleic acid
amplification tests (such as the Xpert MTB/RIF assay), and detection of lipoarabinomannan antigen in urine. In
addition, new molecular diagnostics now permit rapid detection of drug resistance. Further development and
implementation of these tools is vital to permit rapid and effective screening for TB in ART services, which is an
essential component of patient care.
The geographical intersection of the HIV pandemic with
the existing global tuberculosis (TB) epidemic has led to
high rates of HIV-associated TB and related mortality
over the past 25 years [1]. During 2008, there were an
estimated 1.4 million incident cases of HIV-associated
TB worldwide, which accounted for 25% (0.5 million)
of global deaths from HIV infection and AIDS [2].
Sub-Saharan Africa bears the brunt of this epidemic,
accounting for 4 of 5 cases of HIV-associated TB world-
wide [2]. TB incidence rates have increased 3–5-fold in
many African countries with a high prevalence of HIV
infection, and in the worst affected countries of South
Africa and Swaziland, 1% of the national population
develops TB each year [2]. The region with the second
highest burden is southern and Southeast Asia, with 13%
of the global caseload.
Extraordinary progress has been made in scaling up
access to antiretroviral therapy (ART) in low- and mid-
dle-income countries (reaching 5.3 million persons by
the end of 2009) [3]. A majority of these persons
(3.9 million) were in sub-Saharan Africa. Scale-up of
ART in settings with a high burden of TB is associated
with a number of opportunities and challenges. ART is
a crucial component of case management of HIV-
associated TB [4], reducing mortality risk by 64%–95%
[5] and halving recurrence rates [6]. In addition, ART has
an important role in the prevention of HIV-associated
TB, reducing risk in treated cohorts by a mean of 67%
(95% confidence interval [CI], 61%–73%) [7]. Further-
more, aggressive ART scale-up could potentially play
a key role in the control of this epidemic [8].
However, high rates of TB also present many chal-
lenges for ART services: TB is a major cause of morbidity
and mortality, concurrent TB treatment and ART is
complex [9, 10], and TB is associated with a substantial
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risk of nosocomial transmission [11]. These challenges are am-
plified greatly by the major difficulties of screening and di-
agnosing TB in this group of patients. This may, in part, explain
why only 4.1% of patients living with HIV infection worldwide
were estimated to have been screened for TB during 2008 [2].
In this article, we describe the burden and impact of TB on
adults accessing ART programs in resource-constrained settings.
We highlight the importance of effective TB screening and reliable
diagnosis and review the range of conventional and novel TB
diagnostic tools available for use in this context. A majority of the
data reported are from sub-Saharan Africa. However, the princi-
ples outlined are relevant to other resource-constrained settings.
HIV PROGRESSION AND TB RISK
HIV infection has a critical impact on the host cell-mediated
response to Mycobacterium tuberculosis [12]. The risk of TB in-
creases 2–3-fold within the first 2 years of HIV seroconversion
[13] and continues to increase as CD4 cell counts decrease
(Figure 1) [14, 16]. HIV-infected individuals with M. tuberculosis
infection have a mean annual risk of developing TB of10% per
year [17]; however, this risk is highly dependent on the degree
of immunodeficiency, the prevailing socioeconomic conditions,
and ongoing risk of TB exposure. Rates of HIV-associated TB
approach 30% per year among persons with the lowest CD4 cell
counts who live in Cape Town, South Africa (Figure 1) [14].
Reported TB incidence rates among patients with advanced
HIV-associated immunodeficiency, however, belie a conceptual
difficulty with regard to the definition of TB disease. The tra-
ditional concept of HIV-infected patients being classified as
either having active TB or not having active TB has been
questioned [18], and the existing paradigm that distinguishes
latent TB infection from active TB disease as distinct binary
states is thought to be overly simplistic. Our understanding of
the host-pathogen dynamics of M. tuberculosis infection has
fundamentally altered in recent years. It is now thought to be
likely that a spectrum of states exists, with different degrees of
immune control and mycobacterial load [19, 20] and that HIV
infection profoundly shifts this spectrum in favor of bacillary
replication (Figure 2) [18].
This concept has important consequences for our un-
derstanding of the burden of TB in ART programs. Because this
patient population has advanced immunodeficiency, many pa-
tients will have prevalent symptomatic TB disease and many
others may have subclinical, actively replicating infection that
may fall near the limits of detection of TB diagnostic assays.
CLINICO-PATHOLOGICAL CHARACTERISTICS
OF HIV-ASSOCIATED TB
The challenge of TB diagnosis in patients in ART programs re-
lates to the blurring of active disease and latent infection and to
the impact of HIV on the clinico-pathological features of TB. The
features of TB in HIV-1–infected individuals with well-preserved
CD4 cell counts are similar to those of individuals with TB but no
HIV-1 coinfection. Progressive immunodeficiency, however, is
associated with an increasing frequency of miliary and
Figure 1. Tuberculosis (TB) incidence rates (cases/100 person-years
and 95% confidence bands) and CD4 cell counts (cells/lL) in a South
African cohort of HIV-infected patients before availability of antiretroviral
therapy (ART; unshaded area) and during ART-induced immune recovery
(shaded area). The shape of the curve at the time of ART initiation
depends on the intensity of TB screening before ART initiation. Figure
adapted from Lawn et al (2010) [8], and data originally adapted from
Holmes et al (2006) [14] and Lawn et al (2009) [15].
Figure 2. Total bacillary load of Mycobacterium tuberculosis in
individuals showing progression from infection to development of
symptomatic tuberculosis (TB) disease. After infection, patients may
retain good immune control of the infection and low bacillary numbers
(quiescent or latent infection). However, subsequent loss of immune
control is associated with increasing bacillary load that initially
remains as subclinical active infection. At some stage, symptoms
develop, leading to presentation of active symptomatic disease. HIV
infection greatly accelerates the progression toward active infection
and disease. Figure adapted from Lawn et al (2010) [18].
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disseminated forms of disease [21, 22], and occult disseminated
TB has also been a frequent finding in postmortem studies in-
volving persons who died with HIV infection or AIDS in sub-
Saharan Africa [23, 24]. Evidence of the impaired tissue in-
flammatory response to infection is seen in the radiographic
appearances of pulmonary TB, with reduced consolidation,
fibrosis, and cavitation [25, 26]. Lack of cavitation in turn results
in low numbers of bacilli in sputum specimens; thus, results of
sputum smear microscopy for acid-fast bacilli are frequently
negative [22, 27].
BURDEN OF TB IN ART PROGRAMS
TB Referrals to ART Programs
HIV-infected patients typically present to health services in
resource-limited settings with advanced immunodeficiency and
opportunistic infections [28], with TB being one of the most
common presentations [29]. The proportion of patients with TB
who undergo HIV testing has increased substantially in recent
years [2], being catalyzed by implementation of the provider-
initiated HIV testing and counseling strategy in TB programs. As
a result, the proportion of patients referred to ART programs
who have a known TB diagnosis has increased substantially in
some settings; for example, this proportion increased from 16%
to 35% of referrals to a South African ART service over a 6-year
period [30].
Prevalent Undiagnosed TB at Baseline
In addition to patients with known TB, there is a large burden of
undiagnosed TB in other patients. The proportion detected is
likely to vary greatly depending on the prevailing TB burden, the
degree of immunodeficiency, and the rigor with which patients
are screened. The prevalence of TB is established most accurately
when all patients are screened for TB regardless of the presence or
absence of symptoms and when high-sensitivity investigations,
such as automated liquid culture, are used [31, 32]. In 2 studies
involving South African cohorts, patients had median CD4 cell
counts of 100 cells/lL, and pulmonary TB was diagnosed in
19% [33] and 25% [34] of patients when sputum samples from
all patients were examined using automated liquid culture.
Data from these 2 South African studies are likely to represent
the upper end of the range of TB prevalence, but similar studies
in ART programs in countries with less severe TB epidemics are
lacking. However, patients attending HIV clinics or voluntary
counseling and testing services in Southeast Asia have been re-
ported to have a TB prevalence of 6%–15% [35–37]. A sys-
tematic review of the yield of TB screening in HIV-infected
patients attending ART and medical clinics in resource-limited
settings found a median prevalence of 8.2% (range, 1%–25%),
detected using a wide range of screening strategies [31]. The
yield was strongly associated with TB prevalence in the country
and the screening strategy.
Incident TB During ART
TB risk persists during ART. Incidence rates are particularly high
during the first few months of ART, although this is strongly
dependent on the intensity of screening at baseline [38].
A proportion of patients with TB at baseline are either asymp-
tomatic or have minimal symptoms and are not clinically rec-
ognized until immune recovery triggers the development of
symptoms during early ART (so-called ‘‘unmasking TB’’) [39].
Under routine program conditions in a Cape Town ART service,
it was estimated that 40% of TB cases presenting during the
first 4 months of ART were caused by unmasking TB [15].
Consistent with this finding, implementation of an intensive
pretreatment screening strategy using liquid culture of induced
sputum samples approximately halved the TB incidence rate
during this period [38].
TB incidence rates diminish rapidly with ongoing immune
recovery during ART. Data from cohort studies in both high-
income and resource-limited settings report TB risk reductions
of 54%–92% in adjusted analyses [5] and a pooled summary
estimate of a 67% reduction (95% CI, 61%–73%) [7]. The re-
duction in TB incidence rates is time-dependent, with ongoing
reductions during the first 2–3 years of treatment [29, 40–43],
reflecting the rate of ART-induced immune recovery [15]. TB
risk is strongly associated with the current CD4 cell count; an
increase in CD4 cell count from,100 cells/lL to .500 cells/lL
is associated with a 10-fold reduction in TB risk [15] (Figure 1).
Data are lacking on how TB prevalence changes over time
during ART, although it is likely that the highest yield of new
cases would be detected by screening persons with poor CD4 cell
count recovery.
POTENTIAL BENEFITS OF TB SCREENING AND
DIAGNOSIS
There is a very strong rationale for screening and rapid TB
diagnosis among patients accessing ART services (Table 1). Ef-
ficient baseline screening is associated with a substantial re-
duction in the risk of incident TB and associated morbidity
during the initial months of ART [38]. TB is the most common
reported cause of death in ART programs and frequently re-
mains undiagnosed [28]. Postmortem data are few; however, in
a series of 25 patients receiving ART who died after hospital
admission in Johannesburg, South Africa, disseminated myco-
bacterial disease was found in 19 [44]. Similarly, in another
South African hospital, approximately half the deaths among
HIV-infected adults were associated with culture-confirmed TB
[45]. Studies are needed to determine whether rapid screening
and diagnosis of TB in this patient group improves survival. In
the absence of effective diagnostic tools, an alternative approach
may be to provide empirical TB treatment to persons at highest
risk of TB and associated mortality [46]. Studies exploring such
a strategy are needed, and one is being planned by the AIDS
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Clinical Trials Group (ACTG5274 REMEMBER trial; Mina
Hosseinipour, personal communication).
TB in patients accessing ART services presents a serious
infection-control hazard [11]. This hazard is likely to be highest
among newly enrolling ART-naive patients who have a high
prevalence of undiagnosed disease and who often spend con-
siderable time with groups of peers preparing for treatment in
over-crowded facilities. Multidrug-resistant (MDR) TB presents
a particularly important threat [11, 47]. Nosocomial trans-
mission was thought to be a key factor in the 2006 outbreak of
extensively drug-resistant TB (XDR-TB) among patients ac-
cessing ART from a district hospital in rural KwaZulu Natal,
South Africa [48]. Screening and rapid diagnosis leading to early
commencement of TB treatment are central to reducing the
period of infectiousness and transmission risk.
In a small minority of patients, the clinical presentation of
unmasking TB during the initial months of ART may be severe,
with immune reconstitution disease causing considerable immu-
nopathology and clinical compromise [39, 49, 50]. In such cases,
effective screening and early TB diagnosis and initiation of TB
treatment may diminish the risk of these severe forms of disease.
World Health Organization (WHO) guidelines recommend
that TB should be diagnosed and treated before initiation of
ART [51]. Difficulties in diagnosing TB may therefore contrib-
ute to delays in initiation of ART, and this may be associated
with considerable mortality risk [52, 53]. Thus, rapid and ef-
fective TB screening and diagnostic strategies are needed to
permit efficient commencement of TB treatment and ART.
Similarly, implementation of isoniazid preventive therapy in
patients with advanced immunodeficiency has been greatly
undermined by the difficulties of reliably excluding active TB.
More reliable screening methods may facilitate greater uptake in
this patient group in whom there is some evidence of an additive
preventive effect when combined with ART [7].
SCREENING AND DIAGNOSTIC METHODS
Symptom Screening
The WHO previously recommended a cough duration of 2–3
weeks as a symptom screen for TB [51, 54]. This is now recognized
as inadequate for HIV-associated TB, with the sensitivity
frequently being found to be ,50% in this patient group [32, 52,
53]. Screening tools that combine multiple symptoms have much
higher sensitivity, albeit with low specificity. A meta-analysis of
10 000 HIV-infected patients actively screened for TB was
conducted to identify an optimum symptom screening algorithm
[55]. The optimum algorithm identified patients with at least 1 of
4 common symptoms (current cough, night sweats, weight loss, or
fever) with a sensitivity of 79% and a specificity of 50%. These
values are very similar to those found in TB screening studies in 2
ART services in South Africa [33, 34]. This new screening tool has
been included in the WHO 2010 guidelines on intensified case
finding and isoniazid preventive therapy [56] and represents an
important step toward more standardized and effective screening.
However, in ART programs in which the prevalence of TB is as
high as 20%–25%, there is a strong argument for microbiological
screening of all patients regardless of the presence or absence of
symptoms [31, 33, 34]. However, the overall clinical benefits and
associated costs are as yet unknown.
Sputum Smear Microscopy
TB diagnosis in resource-limited settings remains heavily reliant
on smear microscopy using direct Ziehl–Neelsen staining of
sputum. Although this method is highly specific, fast, and rela-
tively inexpensive, it is operator dependent and its use is greatly
impaired in the context of HIV infection. A concentration of
10 000 bacilli per mL of sputum is required for a smear result to
be positive; the higher the bacillary concentration is above this
threshold, the greater the likelihood of positivity. However, lack of
pulmonary cavitation and the resulting low bacillary concen-
trations in sputum means that sputum microscopy results are
usually negative in more than half of patients with HIV-associated
TB [27, 32]. Advancing immunodeficiency is associated with
increased likelihood of negative smear results; in TB screening
studies in South African ART cohorts, .80% of culture-proven
TB cases were sputum smear–negative [33, 34].
Although newer technologies are clearly needed, efforts have
been made to improve the performance of smear microscopy. In
a meta-analysis, sputum processing with bleach or sodium hy-
droxide and centrifugation was associated with a mean increase
in the sensitivity of smear microscopy of 13% [57]. Fluorescence
microscopy also increases sensitivity by 10% and retains
Table 1. Summary of Potential Benefits of Baseline Screening and Rapid Diagnosis of Tuberculosis (TB) Among Patients Entering
Antiretroviral Treatment (ART) Services
Potential benefit Reference
Reduction in morbidity [38]
Reduction in mortality [28, 44]
Reduced hazard of nosocomial TB transmission [11]
Reduced risk of unmasking TB immune reconstitution disease [38, 39]
Facilitation of more efficient clinical decision making, reducing delays in ART initiation .
Reliable exclusion of active TB may permit use of isoniazid preventive therapy [7]
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specificity similar to that of conventional Ziehl–Neelsen staining
[58]. This technology permits more efficient reading of slides,
which is critical to improving laboratory performance. Although
traditional fluorescence microscopes are expensive, cheaper
fluorescence microscopes with light-emitting diodes are equally
sensitive and were endorsed by the WHO in 2009 [59]. In ad-
dition, the WHO made policy changes in 2007 to permit TB
diagnosis to be based on 1 rather than 2 positive sputum smear
results [51]. The number of sputum specimens needed to
be examined before a diagnosis of smear-negative TB could
be made was also reduced from 3 to 2.
Chest Radiography
The pulmonary radiographic features of TB are markedly af-
fected by HIV coinfection and progressive immunodeficiency
[25, 26]. In addition, the high cost, limited availability in many
settings, and difficulties in interpretation by health care workers
substantially undermine the usefulness of radiography in TB
diagnosis in patients accessing ART services. In a study involving
such patients in Cape Town, the sensitivity of any radiographic
abnormalities consistent with TB was just 68% and the speci-
ficity was 53% [60]. Thus, one-third of patients found to have
sputum culture–positive TB by active screening had completely
normal chest radiograph findings.
However, chest radiology has an important role in diagnosis of
other HIV-related pulmonary diseases, which are also common
in this patient group. When used in combination with symptom
screening algorithms to rule out TB, the addition of radiography
may increase sensitivity further and, therefore, may have use in
screening before use of isoniazid preventive therapy [55].
Sputum Culture
Automated liquid culture systems are the gold standard for TB
diagnosis and are of great usefulness in this patient population in
whom most TB is sputum smear–negative. Liquid culture is
considerably more rapid and has a greater yield than does culture
using solid media. In 2007, these assays were recommended by
the WHO to be used in combination with antigen-based species
confirmation for TB diagnosis and for drug-susceptibility testing
in low- and middle-income countries [61]. However, these
culture systems are expensive and prone to contamination.
Despite its invaluable role observed in TB diagnosis among pa-
tients accessing ART services [33, 34], culture-based diagnosis is
unavailable in most resource-limited settings. Thus, alternative
inexpensive, noncommercial culture and drug-susceptibility
testing methods were also endorsed by the WHO in 2009 for use
as an interim solution in resource-constrained settings [59].
These include microscopically observed drug susceptibility
(MODS) and the nitrate reductase assay.
The sensitivity of culture when screening patients for pul-
monary TB before ART depends substantially on the number of
sputum samples analyzed. In a study using automated liquid
culture of sputum samples from patients starting ART in Cape
Town, 2 samples were collected [34]. The incremental yield of
the second sample was 22% [62], which is similar to the 17%
incremental yield observed a study screening for HIV-associated
TB in Southeast Asia [36]. In the latter study, a third sputum
culture identified 10% of the overall yield of pulmonary TB
cases, indicating that a large majority of cases could be
diagnosed on the basis of culture of 2 samples.
The time to culture positivity is prolonged in this patient
population, reflecting low concentrations of mycobacteria in
sputum. Even with use of automated liquid culture, the mean
time to positivity was .3 weeks in a study in Cape Town [34].
Such delays may contribute to morbidity, mortality, nosocomial
TB transmission, and delayed decision-making regarding ART
initiation. The time to positivity of the MODS assay appears to be
less dependent on sputum smear status, with the median time to
positivity for sputum smear–negative sputum samples reported
to be 7 days, compared with 6 days in sputum smear–positive
samples [63]. The usefulness of MODS should be evaluated in
this patient population.
Testing Nonpulmonary Clinical Samples
A comprehensive evaluation of the additional value of ex-
trapulmonary samples was made in a study in Southeast Asia in
which patients (median CD4 cell count, 281 cells/lL) attending
HIV clinics were intensively screened for TB, with collection of
3 sputum samples together with stool, urine, blood culture, and
(when possible) lymph node aspirates [36]. TB was diagnosed in
14% of patients overall; 86% of these diagnoses were made using
sputum samples, and the additional yield of 14% of diagnoses
were made using culture of nonpulmonary samples. The greatest
yield from nonpulmonary samples was from lymph node aspi-
rate samples, which provided an incremental yield of 6% when
used in addition to liquid culture of 2 sputum samples [36].
Antigen Detection
Although current commercially available serological tests for TB
are of little diagnostic value [64], mycobacterial antigen de-
tection is theoretically more attractive, overcoming many of the
limitations inherent in immune-based assays. A simple, com-
mercially available assay is able to detect lipoarabinomannan
(LAM) excreted in the urine of patients with TB. Although the
sensitivity has been disappointing in HIV-uninfected patients
[65], moderate sensitivity and high specificity has been observed
in HIV-infected patients in South Africa [34, 66, 67].
In each of these studies [34, 66, 67], the sensitivity of the LAM
enzyme-linked immunosorbent assay (ELISA) exceeded that of
sputum smear microscopy, and there was an incremental yield
when these tests were used in combination. The sensitivity of the
LAM ELISA was highest among patients with the lowest CD4
cell counts (Figure 3). In ambulatory patients screened before
ART and in hospitalized HIV-infected patients with suspected
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TB who had CD4 cell counts,50 cells/lL, the sensitivities of the
assay were 67% and 85%, respectively [34, 64]. Very high
specificity was observed in both studies. Greater sensitivity at
lower CD4 cell counts is consistent with the fact that patients
with markedly impaired antimycobacterial immune responses
tend to have disseminated, multibacillary disease, and thus, the
likelihood of mycobacterial antigenuria is likely to be increased.
A simplified lateral flow version of this assay (dip-stick) is
currently being evaluated [65]. If the sensitivity and specificity of
this is at least comparable to that of ELISA, it could be used as
a simple and cheap point-of-care test incorporated in a di-
agnostic screening algorithm for outpatients accessing ART or
for HIV-infected inpatients. This would reduce the mean time to
TB diagnosis by 3 weeks in approximately half the patients
with TB who had CD4 cell counts ,100 cells/lL in a South
African ART program [34].
Nucleic Acid Amplification Tests (NAATs)
NAATs represent the most promising development for rapid
diagnosis of TB and rapid drug-susceptibility testing [68].
However, their technical complexity has hindered widespread
implementation in resource-limited settings. Moreover, their
usefulness when applied directly to smear-negative sputum
samples has been limited to date. However, considerable prog-
ress has been made in developing simplified versions with higher
sensitivity for smear-negative disease. A manual NAAT using
loop-mediated isothermal amplification with a simple visual
colorimetric read-out showed high specificity but only moderate
sensitivity for smear-negative culture-positive disease [69]. A
revised prototype is undergoing further evaluation in peripheral
laboratory facilities in resource-constrained settings.
The most important development to date is a sensitive and
specific fully automated and commercially available NAAT as-
say, which has been developed for use outside reference labo-
ratory centers [70, 71]. The Xpert MTB/RIF assay (Cepheid)
uses a series of molecular beacons and real-time polymerase
chain reaction technology to detect M. tuberculosis and the rpoB
rifampicin resistance mutation. The cartridge-based system
dispenses with the need for prior sputum processing and re-
quires minimal laboratory expertise; furthermore, results are
available,2 hours, permitting a specific TB diagnosis and rapid
detection of rifampicin resistance. A large multicountry evalu-
ation found excellent performance characteristics, including
sensitivities of 72.5%, 85.1%, and 90.2% for sputum smear–
negative disease when processing 1, 2, or 3 sputum specimens,
respectively [71].
However, when used to screen for TB in patients starting
ART, the Xpert MTB/RIF assay may be stretched to its limits
of detection [62]. Laboratory evaluations have shown a limit of
detection (as defined by 95% sensitivity) of 131 bacilli per mL
of sputum [70], whereas automated liquid culture systems have
a sensitivity range of 10–100 organisms per mL. It will be im-
portant to assess the sensitivity of the Xpert MTB/RIF assay
among patients commencing ART in whom bacillary numbers
in sputum are often very low. Multiple samples may be needed
to achieve adequate sensitivity, which will increase costs. How-
ever, the simplicity of use of this technology means that the
machines could be located at ART clinics and used by health care
personnel after minimal training. Such field evaluations of this
technology are ongoing.
Interferon-g Release Assays
Interferon-c release assays detect interferon-c production from
peripheral blood mononuclear cells after in vitro stimulation
with antigens, such as ESAT-6 and CFP-10 (immunodominant
antigens expressed by members of the M. tuberculosis complex)
[72]. These assays have a sensitivity of 80%–90% among patients
with confirmed TB but are unable to distinguish between active
and latent disease, resulting in very poor specificity as a TB di-
agnostic in populations in settings with a high TB burden where
prevalence of latent infection is high. These assays therefore have
no role for TB diagnosis in resource-limited settings.
Rapid Detection of Drug-Resistant TB
The global emergence of the MDR-TB epidemic provides
a particular threat to patients in ART services [11], as evidenced
by the devastating outbreak of XDR-TB in rural KwaZulu Natal,
South Africa, during 2005–2006 [48]. The outbreak was believed
to have been caused by nosocomial transmission in patients
Figure 3. Sensitivity of a commercially available enzyme-linked immu-
nosorbent assay (ELISA) to detect lipoarabinomannan (LAM) in urine
samples for diagnosis of tuberculosis (TB) in a cohort of patients
accessing antiretroviral treatment (ART) in a South African township. The
sensitivity of sputum microscopy and the LAM ELISA are shown
individually and combined (either positive), compared with a gold
standard of automated liquid culture of 2 sputum samples. Data are
stratified by CD4 cell count. Data are from Lawn et al (2009) [34].
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accessing ART at a district hospital. Expanded capacity for TB
screening and rapid phenotypic or genotypic resistance testing is
urgently needed.
To enhance capacity for rapid diagnosis of MDR-TB, in
2008, the WHO approved use of line probe assays for the rapid
molecular detection of drug resistance in smear-positive
specimens or culture isolates [73, 74]. Two commercial line
probe assays have shown high accuracy when applied to culture
isolates, and one of these, the GenoType MTBDRplus assay
(Hain Lifescience GmbH), has also shown very good perfor-
mance characteristics when applied directly to smear-positive
sputum specimens [75, 76].
In 2009, the GenoType MTBDRsl assay (Hain Lifescience
GmbH) became available; it is also able to detect resistance to
fluoroquinolones, aminoglycosides, and ethambutol in culture
isolates or smear-positive sputum specimens [77]. When used
together with the GenoType MTBDRplus assay (which detects
resistance to rifampicin and isoniazid), the combined results
potentially provide a means of rapid detection of XDR-TB. Use
of such molecular assays reduces the time to diagnosis of MDR-
TB and XDR-TB from weeks or months to days. However, line
probe assays are technically demanding and require complex
infrastructure and highly trained staff; thus, their use is limited
to centralized laboratories. Their impact on patient outcomes
has yet to be demonstrated. Simplified automated NAATs, such
as the Xpert MTB/RIF assay, may provide a simpler means for
rapid detection of drug resistance.
CONCLUSIONS
TB represents a huge challenge to ART services in resource-
limited settings, and this requires the implementation of routine,
systematic, and effective screening. Progress has been made in
developing a better screening algorithm, and there is a de-
velopmental pipeline of very promising new diagnostic technol-
ogies that require evaluation in this specific patient population.
Newer culture-based systems, simplified NAATs, and urinary
antigen detection may each play an important role, depending on
the setting, local laboratory capacity, and human resources
available. Implementation of these new tools is vital to permit
rapid and effective screening for TB in ART services, which must
be regarded as an essential component of patient care.
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